

FASTER. SMARTER. MORE FLEXIBLE.

The next step in your
patient's smarter journey



TH90D01 Activa™ Patient Programmer



WR9200 Recharger



Activa™ RC


HELP YOUR PATIENTS TAKE CHARGE

with a wireless recharger that's
faster*, easier to use, and provides
more flexibility and customization
than ever.

Medtronic
Further. Together

AROUND THEIR SCHEDULE.

It's time to give your patients more flexibility. With faster feedback, and a coupling area that's designed for a more consistent connection, patients may find it easier to charge while on the go. And with speed and temperature features that are customizable to each patient's preference—they'll be ready for an experience that fits their lifestyle—without holding them back.



- Mobility while charging
- Patient can select between speed and temperature to customize the charge session that fits their needs
- Proprietary recharge algorithm to maintain safe temperatures

A SMARTER CHARGING EXPERIENCE IS IN THEIR HANDS.

The recharger is here to help patients get more of their time back—with an improved recharging experience that's faster*, smarter, and more flexible—for a recharging experience that encourages a positive outlook on their therapy journey.



THE SPEED THEY NEED.

The wait for a full neurostimulator charge may now be shorter* than ever. With a larger coupling area that enables a stronger, faster, more consistent connection—patients can spend more time on what they enjoy in life, and less time maintaining their therapy.


Patients who recharge are ready for an experience that works around their lives—not the other way around. And the Activa™ RC Recharger is here to deliver, with updated features that offer the potential for faster charging, increased ease of use, and the flexibility to fine-tune for comfort while taking it on the go. For a lifestyle that won't slow down, give patients the tools to feel up to the challenge—because they're in charge.

- Larger coupling area
- More consistent connection
- Full charge in less time*

THE EASE THEY DESIRE.

Neurostimulator charging has never been easier. Now, patients can begin at the press of a single button—and check status at the blink of an eye. With the intuitive design of the system, a streamlined charging procedure and insights available via the recharger companion app, patients can be confident they're getting an optimal charge, every time.

- Charge initiated with the push of a single button
- Simplified components and charging interaction
- Easy-to-understand indicators
- Optional companion app provides additional insights to charge session and patient customization options



Brief Statement: Medtronic DBS Therapy for Parkinson's Disease and Tremor

Medtronic DBS Therapy for Parkinson's Disease and Tremor: Product labeling must be reviewed prior to use for detailed disclosure of risks.

INDICATIONS:

Medtronic DBS Therapy for Parkinson's Disease: Bilateral stimulation of the internal globus pallidus (GPI) or the subthalamic nucleus (STN) using Medtronic DBS Therapy for Parkinson's Disease is indicated for adjunctive therapy in reducing some of the symptoms in individuals with levodopa-responsive Parkinson's disease of at least 4 years' duration that are not adequately controlled with medication, including motor complications of recent onset (from 4 months to 3 years) or motor complications of longer-standing duration.

Medtronic DBS Therapy for Tremor: Unilateral thalamic stimulation of the ventral intermediate nucleus (VIM) using Medtronic DBS Therapy for Tremor is indicated for the suppression of tremor in the upper extremity. The system is intended for use in patients who are diagnosed with essential tremor or parkinsonian tremor not adequately controlled by medications and where the tremor constitutes a significant functional disability.

CONTRAINDICATIONS: Medtronic DBS Therapy is contraindicated (not allowed) for patients who are unable to properly operate the neurostimulator and patients for whom test stimulation is unsuccessful. The following procedures are contraindicated for patients with DBS systems: diathermy (e.g., shortwave diathermy, microwave diathermy or therapeutic ultrasound diathermy), which can cause neurostimulation system or tissue damage and can result in severe injury or death; Transcranial Magnetic Stimulation (TMS); and certain MRI procedures using a full body transmit radio-frequency (RF) coil, a receive-only head coil, or a head transmit coil that extends over the chest area if the patient has an implanted Soletra™ Model 7426 Neurostimulator, Kinetra™ Model 7428 Neurostimulator, Activa™ SC Model 37602 Neurostimulator, or Model 64001 or 64002 pocket adaptor.

WARNINGS: There is a potential risk of brain tissue damage using stimulation parameter settings of high amplitudes and wide pulse widths and a potential risk to drive tremor (cause tremor to occur at the same frequency as the programmed frequency) using low frequency settings. Extreme care should be used with lead implantation in patients with an increased risk of intracranial hemorrhage. Sources of electromagnetic interference (EMI) may cause device damage or patient injury. Theft detectors and security screening devices may cause stimulation to switch ON or OFF and may cause some patients to experience a momentary increase in perceived stimulation. The DBS System may be affected by or adversely affect medical equipment such as cardiac pacemakers or therapies, cardioverter/defibrillators, external defibrillators, ultrasonic equipment, electrocautery, or radiation therapy. MRI conditions that may cause excessive heating at the lead electrodes which can result in serious and permanent injury including coma, paralysis, or death, or that may cause device damage, include: neurostimulator implant location other than pectoral and abdominal regions; unapproved MRI parameters; partial system explants ("abandoned systems"); misidentification of neurostimulator model numbers; and broken conductor wires (in the lead, extension or pocket adaptor). The safety of electroconvulsive therapy (ECT) in patients receiving DBS Therapy has not been established. Abrupt cessation of stimulation should be avoided as it may cause a return of disease symptoms, in some cases with intensity greater than was experienced prior to system implant ("rebound" effect). New onset or worsening depression, suicidal ideations, suicide attempts, and suicide have been reported.

Patients should avoid activities that may put undue stress on the implanted components of the neurostimulation system. Activities that include sudden, excessive or repetitive bending, twisting, or stretching can cause component fracture or dislodgement that may result in loss of stimulation, intermittent stimulation, stimulation at the fracture site, and additional surgery to replace or reposition the component. Patients should avoid manipulating the implanted system components or burr hole site as this can result in component damage, lead dislodgement, skin erosion, or stimulation at the implant site. Patients should not dive below 10 meters (33 feet) of water or enter hyperbaric chambers above 2.0 atmospheres absolute (ATA) as this could damage the neurostimulation system, before diving or using a hyperbaric chamber, patients should discuss the effects of high pressure with their clinician. Patients using a rechargeable neurostimulator must not place the recharger over a medical device with which it is not compatible (eg, other neurostimulators, pacemaker, defibrillator, insulin pump). The recharger could accidentally change the operation of the medical device, which could result in a medical emergency. Patients should not use the recharger on an unhealed wound as the recharger system is not sterile and contact with the wound may cause an infection.

PRECAUTIONS: Loss of coordination in activities such as swimming may occur. Patients using a rechargeable neurostimulator for Parkinson's disease or essential tremor should check for skin irritation or redness near the neurostimulator during or after recharging, and contact their physician if symptoms persist.

ADVERSE EVENTS: Adverse events related to the therapy, device, or procedure can include intracranial hemorrhage, cerebral infarction, CSF leak, pneumocephalus, seizures, surgical site complications (including pain, infection, dehiscence, erosion, seroma, and hematoma), meningitis, encephalitis, brain abscess, cerebral edema, aseptic cyst formation, device complications (including lead fracture and device migration) that may require revision or explant, extension fibrosis (tightening or bowstringing), new or exacerbation of neurological symptoms (including vision disorders, speech and swallowing disorders, motor coordination and balance disorders, sensory disturbances, cognitive impairment, and sleep disorders), psychiatric and behavioral disorders (including psychosis and abnormal thinking), cough, shocking or jolting sensation, ineffective therapy and weight gain or loss.

Safety and effectiveness has not been established for patients with neurological disease other than idiopathic Parkinson's disease or Essential Tremor, previous surgical ablation procedures, dementia, coagulopathies, or moderate to severe depression, patients who are pregnant, or patients under 18 years. Safety and effectiveness of Medtronic DBS Therapy for Tremor has not been established for bilateral stimulation or for patients over 80 years of age.

USA Rx only Rev 03/20

*Patients who had long charge times with 37651 Medtronic Implantable Neurostimulator Recharger (due to tilt, implant depth, and other challenges) have the opportunity to experience improvement with the wireless recharger.

Medtronic

710 Medtronic Parkway
Minneapolis, MN 55432-5604
USA

Tel: (763) 514-4000

Fax: (763) 514-4879

Toll-free: 1 (800) 328-2518

24-hour technical support for
physicians and medical professionals

UC202014953 EN © Medtronic, Inc.

2020. Minneapolis, MN. All Rights Reserved.

medtronic.com